Quanterix is proud to sponsor the ALS Drug Development Summit 2025, taking place May 12-14 in Boston, MA.

This event gathers over 200 leaders from pharma, biotech, academia, and patient advocacy to advance ALS drug development. Topics include novel therapeutic targets (STMN2, UNC13A, etc.), precision biomarkers for early detection, patient-centric trial designs, and collaborative efforts by consortia like Target ALS, Answer ALS, and AMP ALS to drive progress.

You can visit the Quanterix team on-site in the exhibit area to learn more about our cutting-edge innovations in biomarker research.

We look forward to connecting with you in Boston!